New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
09:08 EDTSTJSt. Jude Medical well-positioned heading into 2015, says Wedbush
Subscribe for More Information
08:53 EDTSTJSt. Jude Medical weakness a buying opportunity, says CRT Capital
CRT Capital would use St. Jude Medical weakness as a buying opportunity based on accelerating EPS growth and expects CardioMEMS to be a $1B revenue opportunity over the next few years. Shares are Buy rated with a $80 price target.
07:45 EDTSTJSt. Jude Medical price target lowered to $66 from $75 at Stifel
Subscribe for More Information
October 15, 2014
08:37 EDTSTJSt. Jude Medical expects AF products revenue to accelerate in FY15
As the company look to FY15, aims to continue to accelerate its sales growth rate. Expects the acceleration to come from its men's heart failure monitor system and chronic pain business. Expects to grow sales faster in FY15 compared to FY14.
08:32 EDTSTJSt. Jude Medical sees YOY currency impact on sales $50M-$60M for Q4
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical reports Q3 total CRM sales $688M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical narrows FY14 adjusted EPS view to $3.97-$3.99 from $3.96-$4.01
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q4 adjusted EPS $1.02-$1.04, consensus $1.04
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical Sees FY14 adjusted EPS $3.97-$3.99, consensus $3.98
Sees FY14 revenue $5.586B-$5.648B, consensus $5.69B.
07:31 EDTSTJSt. Jude Medical reports Q3 adjusted EPS 97c, consensus 96c
Reports Q3 revenue $1.37B, consensus $1.38B.
October 14, 2014
15:29 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
October 13, 2014
07:25 EDTSTJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use